Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Oxervate (cenegermin-bkbj) is indicated for the treatment of neurotrophic keratitis.
• This summary is based on the review of one randomized controlled trial(s). ^[1]
• Primary Outcome – Healing of Neurotrophic Lesion: At week 8, 69.6% of cenegermin-treated patients achieved less than 0.5 mm of lesion staining compared to 29.2% of vehicle-treated patients (difference of +40.4%; 95% CI, 14.2%-66.6%; P = 0.006). Additionally, 65.2% of cenegermin-treated patients achieved 0 mm of lesion staining and no other residual staining compared to 16.7% of vehicle-treated patients (difference of +48.6%; 95% CI, 24.0%-73.1%; P < 0.001).
• Secondary Outcome – Corneal Healing at 4 Weeks: The conservative measure of corneal healing showed statistical significance at week 4, favoring cenegermin over the vehicle.
• Other Secondary Outcomes: The cenegermin group exhibited statistically significant reductions in lesion size and lower disease progression rates compared to the vehicle group during masked treatment.
• Cenegermin was well tolerated, with mostly local, mild, and transient adverse effects reported.
• The study does not specify any significant safety concerns or adverse effects in specific population types or subgroups.